Amgen Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 253 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Amgen Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Amgen Inc. - Product Pipeline Review - 2014', provides an overview of the Amgen Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amgen Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Amgen Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Amgen Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Amgen Inc.'s pipeline products

Reasons to buy

- Evaluate Amgen Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Amgen Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Amgen Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Amgen Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amgen Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Amgen Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Amgen Inc. Snapshot 7
Amgen Inc. Overview 7
Key Information 7
Key Facts 7
Amgen Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Amgen Inc. - Pipeline Review 17
Pipeline Products by Stage of Development 17
Pipeline Products - Monotherapy 18
Pipeline Products - Partnered Products 19
Pipeline Products - Out-Licensed Products 21
Amgen Inc. - Pipeline Products Glance 25
Amgen Inc. - Late Stage Pipeline Products 25
Amgen Inc. - Clinical Stage Pipeline Products 29
Amgen Inc. - Early Stage Pipeline Products 33
Amgen Inc. - Unknown Stage Pipeline Products 37
Amgen Inc. - Drug Profiles 38
darbepoetin alfa 38
denosumab 40
panitumumab 43
pegfilgrastim 46
romiplostim 48
adalimumab biosimilar 50
bevacizumab biosimilar 51
bixalomer 52
blinatumomab 54
brodalumab 57
cinacalcet hydrochloride 59
evolocumab 61
ivabradine 63
rilotumumab 65
romosozumab 67
talimogene laherparepvec 69
trastuzumab biosimilar 71
trebananib 72
velcalcetide 75
abrilumab 77
AMG-139 79
AMG-151 80
AMG-157 82
AMG-334 83
AMG-337 84
fulranumab 85
ganitumab 87
omecamtiv mecarbil 90
AMG-232 92
AMG-172 93
AMG-208 95
AMG-282 96
AMG-319 97
AMG-333 98
AMG-357 99
AMG-557 100
AMG-581 102
AMG-595 103
AMG-729 105
AMG-780 106
AMG-811 107
AMG-820 109
AMG-876 110
AMG-900 111
mogamulizumab 113
MT-111 115
MT-112 117
solitomab 119
Activin Type IIB Receptor Antagonist for Cancer Cachexia 121
AM-1638 122
AM-6226 123
AM-8553 124
AMG-161 125
AMG-1694 126
AMG-3969 127
AMG-511 128
AMG-925 129
Amgen-3 130
Amgen-4 131
Beta-Secretase 1 Inhibitors for Alzheimer Disease 132
Biaryl Amide 133
BiTE Antibody Targetting CD33 134
BiTE For Solid Tumors 135
Calcimimetic-18 for Secondary Hyperparathyroidism 136
cetuximab 137
cetuximab biosimilar 138
Dual PI3K Beta/Delta Inhibitors for Rheumatoid Arthritis And Inflammation 139
EP2 Antagonists for Alzheimer Disease 140
First Generation Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia And Type 2 Diabetes 141
GPR142 Agonists for Type 2 Diabetes 142
Human Beta Secretase Inhibitor 143
Keto-benzimidazoles 144
MCSP BiTE Antibody 145
morpholinone-27 146
MT-204 147
Multiple Myeloma BiTE 148
Phosphoinositide Kinase Inhibitor for Inflammation And Oncology 149
Recombinant Fc-FGF21 150
rituximab biosimilar 151
Second Generation Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia And Type 2 Diabetes 152
Small Molecule to Agonize GPR119 for Undisclosed Indication 153
Triazine Sulfonamide 154
AA-71 155
Cdc7 Kinase Inhibitors Program 156
Drugs for Inflammatory Bowel Disease 157
Morpholinone-10 158
Morpholinone-16 159
Small Molecule Inhibits Tankyrase for Cancer 160
Small Molecule Targeting GPR119 161
Amgen Inc. - Pipeline Analysis 162
Amgen Inc. - Pipeline Products by Target 162
Amgen Inc. - Pipeline Products by Route of Administration 168
Amgen Inc. - Pipeline Products by Molecule Type 169
Amgen Inc. - Pipeline Products by Mechanism of Action 171
Amgen Inc. - Recent Pipeline Updates 178
Amgen Inc. - Dormant Projects 224
Amgen Inc. - Discontinued Pipeline Products 229
Discontinued Pipeline Product Profiles 229
Amgen Inc. - Company Statement 235
Amgen Inc. - Locations And Subsidiaries 238
Head Office 238
Other Locations & Subsidiaries 238
Amgen Inc. - Key Manufacturing Facilities 245
Appendix 246
Methodology 246
Coverage 246
Secondary Research 246
Primary Research 246
Expert Panel Validation 246
Contact Us 247
Disclaimer 247

List of Tables
Amgen Inc., Key Information 13
Amgen Inc., Key Facts 13
Amgen Inc. - Pipeline by Indication, 2014 15
Amgen Inc. - Pipeline by Stage of Development, 2014 23
Amgen Inc. - Monotherapy Products in Pipeline, 2014 24
Amgen Inc. - Partnered Products in Pipeline, 2014 25
Amgen Inc. - Partnered Products/ Combination Treatment Modalities, 2014 26
Amgen Inc. - Out-Licensed Products in Pipeline, 2014 27
Amgen Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 28
Amgen Inc. - Pre-Registration, 2014 31
Amgen Inc. - Filing rejected/Withdrawn, 2014 32
Amgen Inc. - Phase III, 2014 33
Amgen Inc. - Phase II, 2014 35
Amgen Inc. - Phase I, 2014 37
Amgen Inc. - Preclinical, 2014 39
Amgen Inc. - Discovery, 2014 42
Amgen Inc. - Unknown, 2014 43
Amgen Inc. - Pipeline by Target, 2014 169
Amgen Inc. - Pipeline by Route of Administration, 2014 174
Amgen Inc. - Pipeline by Molecule Type, 2014 176
Amgen Inc. - Pipeline Products by Mechanism of Action, 2014 178
Amgen Inc. - Recent Pipeline Updates, 2014 184
Amgen Inc. - Dormant Developmental Projects,2014 230
Amgen Inc. - Discontinued Pipeline Products, 2014 235
Amgen Inc., Other Locations 244
Amgen Inc., Subsidiaries 247
Amgen Inc., Key Manufacturing Facilities 251